#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC

One of Eli Lilly’s newest R&D partners revealed some new data at #ASCO21 for an in-house program, and it’s one that could cover a broad …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AS­CO21: Eli Lil­ly-part­nered Merus re­veals new da­ta for NRG1 fu­sion can­cers in­clud­ing pan­cre­at­ic and NSCLC